{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:46:27Z","timestamp":1789980387692,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ijaaonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ijantimicag.2014.09.017","type":"journal-article","created":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T16:15:55Z","timestamp":1414858555000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic\/pharmacodynamic model"],"prefix":"10.1016","volume":"45","author":[{"given":"Luning","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwin K.B.","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midas B.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Derendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2014.09.017_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000238643","article-title":"Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora","volume":"34","author":"Hoepelman","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1128\/AAC.26.6.870","article-title":"Single-drug versus combination empirical therapy for Gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia","volume":"26","author":"Piccart","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-4684-8953-8_30","article-title":"Randomized multi center study comparing nephrotoxicity of ceftazidime versus the combination of piperacillin and netilmicin with and without furosemide","volume":"252","author":"Mondorf","year":"1989","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(04)01108-9","article-title":"Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis","volume":"4","author":"Safdar","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0030","series-title":"Developing antimicrobial drugs-general considerations for clinical trials (draft guidance)","author":"US Food and Drug Administration. Guidance for industry","year":"1998"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0035","series-title":"Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","author":"European Medicines Agency","year":"2000"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0040","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1128\/AAC.01400-07","article-title":"In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6\u2032-APH2 enzyme","volume":"52","author":"Li","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jchromb.2005.06.045","article-title":"High-performance liquid chromatographic determination of vertilmicin in rat plasma using sensitive fluorometric derivatization","volume":"828","author":"Liu","year":"2005","journal-title":"J Chromatogr B: Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2003.08.043","article-title":"Determination of vertilmicin in rat serum by high-performance liquid chromatography using 1-fluoro-2,4-dinitrobenzene derivatization","volume":"798","author":"Zhou","year":"2003","journal-title":"J Chromatogr B: Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13318-010-0007-8","article-title":"Pharmacokinetics of vertilmicin, a novel aminoglycoside antibiotic, in rats and dogs","volume":"35","author":"Zhou","year":"2010","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0060","series-title":"6th National Conference of Clinical Pharmacology on Antimicrobial Agents","first-page":"194","article-title":"Determination of vertilmicin in human serum and urine by HPLC using pre-column derivatization","author":"Wei","year":"2006"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0065","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1128\/AAC.00223-09","article-title":"In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic","volume":"53","author":"You","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijantimicag.2006.08.049","article-title":"Pharmacokinetic\/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains","volume":"29","author":"Treyaprasert","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0075","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1128\/AAC.00633-09","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus","volume":"53","author":"Schmidt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0080","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1128\/AAC.40.8.1785","article-title":"Gentamicin concentrations in human subcutaneous tissue","volume":"40","author":"Lorentzen","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0085","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/AAC.2.3.214","article-title":"Serum protein binding of the aminoglycoside antibiotics","volume":"2","author":"Gordon","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0090","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1128\/AAC.39.3.650","article-title":"Experience with a once-daily aminoglycoside program administered to 2,184 adult patients","volume":"39","author":"Nicolau","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dki086","article-title":"Modelling time\u2013kill studies to discern the pharmacodynamics of meropenem","volume":"55","author":"Tam","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2003.07.009","article-title":"PK-PD modelling of the effect of cefaclor on four different bacterial strains","volume":"23","author":"de la Pe\u00f1a","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1011907920641","article-title":"Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships: concepts and perspectives","volume":"16","author":"Derendorf","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01952257","article-title":"Combinated effects I Announcement \u2013 implements to the problem","volume":"114","author":"Loewe","year":"1926","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clinthera.2005.06.013","article-title":"A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit","volume":"27","author":"Mouton","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.32.3.298","article-title":"Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers","volume":"32","author":"Lam","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0125","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2165\/11597020-000000000-00000","article-title":"Pharmacological considerations for the proper clinical use of aminoglycosides","volume":"71","author":"Pagkalis","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0130","first-page":"364","article-title":"In vitro combinations of antibiotics and phytochemicals against Pseudomonas aeruginosa","volume":"42","author":"Sakharkar","year":"2009","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1574-6968.2007.00753.x","article-title":"Identification of a new gene PA5017 involved in flagella-mediated motility, chemotaxis and biofilm formation in Pseudomonas aeruginosa","volume":"272","author":"Li","year":"2007","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.ijantimicag.2014.09.017_bib0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/AAC.13.5.827","article-title":"Unpredictable response of Pseudomonas aeruginosa to synergistic antibiotic combinations in vitro","volume":"13","author":"Heineman","year":"1978","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914003252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857914003252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T03:51:17Z","timestamp":1746503477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857914003252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0924857914003252"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic\/pharmacodynamic model","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}